
Sign up to save your podcasts
Or
Suboptimal dosing of renin-angiotensin-aldosterone system inhibitors (RAASi) therapy is associated with doubling of mortality. Experts discuss new options for intensification of RAASi in heart failure with reduced ejection fraction (HFrEF). Credit available for this activity expires: 9/29/2024 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/996906?ecd=bdc_podcast_libsyn_mscpedu
4
77 ratings
Suboptimal dosing of renin-angiotensin-aldosterone system inhibitors (RAASi) therapy is associated with doubling of mortality. Experts discuss new options for intensification of RAASi in heart failure with reduced ejection fraction (HFrEF). Credit available for this activity expires: 9/29/2024 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/996906?ecd=bdc_podcast_libsyn_mscpedu
127 Listeners
13 Listeners
315 Listeners
852 Listeners
476 Listeners
693 Listeners
16 Listeners
282 Listeners
252 Listeners
3,327 Listeners
247 Listeners
91 Listeners
1,087 Listeners
174 Listeners
510 Listeners
318 Listeners
59 Listeners
24 Listeners
289 Listeners